Cingulate receives $3M grant from private foundation to accelerate CTx-2103 (buspirone) development

Cingulate Inc.

Grant of $3M in three $1M tranches; first payment May 1, 2025, others upon formulation and development milestones.
Non-dilutive funding; contingent royalty of $500K per quarter after first commercial sale, max cumulative $3.5M.
CTx-2103 (buspirone) potential first once-daily formulation for anxiety; U.S. market $5.5B, global $11.6B.
Grant expands pipeline and validates Cingulate's proprietary Precision Timed Release drug delivery platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.